厄贝沙坦联合卡维地洛治疗心力衰竭的临床效果与安全性分析  

Clinical Effect and Safety of Irbesartan Combined with Carvedilol in the Treatment of Heart Failure

作　　者：陈雅丽[1] 闫佩佩[1] 白雪洋[2] 王丽蕊[3] CHEN Yali;YAN Peipei;BAI Xueyang;WANG Lirui(General Department,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Cardiology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Surgical ICU,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院综合科一,河南郑州450052 [2]郑州大学第一附属医院心内科,河南郑州450052 [3]郑州大学第一附属医院外科ICU,河南郑州450052

出　　处：《临床医学工程》2022年第3期361-362,共2页Clinical Medicine & Engineering

摘　　要：目的 探讨厄贝沙坦联合卡维地洛治疗心力衰竭的临床效果与安全性。方法 选取2020年1月至2020年10月我院收治的110例心力衰竭患者,按治疗方法不同分为两组各55例。对照组采用厄贝沙坦治疗,实验组采用厄贝沙坦联合卡维地洛治疗,比较两组的治疗效果、心功能指标及不良反应情况。结果 实验组治疗总有效率为92.73%,高于对照组的74.55%(P<0.05)。治疗后,实验组的LVESD、 LVEDD均低于对照组,LVEF高于对照组(P <0.05)。两组的不良反应发生率比较无统计学差异(P>0.05)。结论 厄贝沙坦联合卡维地洛治疗心力衰竭的效果显著,有助于改善患者心功能,且不会明显增加不良反应。Objective To explore the clinical effect and safety of irbesartan combined with carvedilol in the treatment of heart failure.Methods 110 patients with heart failure admitted to our hospital from January 2020 to October 2020 were selected and divided into two groups according to different treatment methods,with 55 cases in each group.The control group was treated with irbesartan,and the experimental group was treated with irbesartan combined with carvedilol.The treatment effect,cardiac function indicators and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the experimental group was 92.73%,higher than 74.55%in the control group(P<0.05).After treatment,the LVESD and LVEDD of the experimental group were lower than those of the control group,and the LVEF was higher than that of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Irbesartan combined with carvedilol in the treatment of heart failure has significant effect,which is helpful to improve the cardiac function of patients,and will not significantly increase the adverse reactions.

关 键 词：心力衰竭 厄贝沙坦 卡维地洛 心功能 安全性 

分 类 号：R541.61[医药卫生—心血管疾病]